Abstract:
Abstract
Background: Hormonal contraception is a type of birth control that uses hormones to prevent
pregnancy. It is also linked to a variety of unfavorable health outcomes, including metabolic
diseases. Metabolic syndrome (MetS) is a group of cardiometabolic risk factors that includes
glucose intolerance, dyslipidemia, hypertension, and central obesity. These risk factors are linked
with an increased risk of cancer, cardiovascular disease and metabolic disorders like T2DM and its
complications. Several studies have shown that the risk of developing MetS-related cardiovascular
disease is prevalent in women who use hormonal contraception. However, there is scarcity of
information in Ethiopia, particularly in the study area.
Objective: To assess the magnitude and determinants of metabolic syndrome among hormonal
contraceptive users attending at family guidance association of Ethiopia, Dessie, Northeast
Ethiopia, 2022.
Methods and Materials: A facility-based cross-sectional study design was implemented from July
3, 2022 to September 25, 2022. A total of 312 samples were recruited through systematic random
sampling technique. Metabolic syndrome was defined according to the standard NCEP-ATP III
criteria. The data was collected by using pretested semi structure questionnaire through face to face
interview, anthropometric and laboratory measurements. The biochemical parameters were
analyzed by using Mindray BS 120 Automated, (China) analyzer. The data were entered into
Epidata version 4.6 and exported to SPSS version 26. Descriptive statistics were summarized using
mean±SD & percentage. Binary logistic regression analysis was used to determine the determinants
of MetS. Variables having a p-value of <0.05 at multivariate logistic regression analysis were
considered to be statistically significant. The data were presented using texts, tables, and figures.
Result: The magnitude of MetS was 26.6% (95% CI; (21.8, 31.4). Having low physical activity
[AOR=3.8, 95% CI: (1.66, 8.76)], Parity ≥4 [AOR=2.83, 95% CI: (1.28, 6.23)], Injectable
Contraceptive use [AOR=2.23, 95% CI: (1.10, 4.61)], and using hormonal contraceptives for a
duration of >48 months [AOR=3.34, 95% CI: (1.36, 8.14)], were determinants of MetS.
Conclusion: The magnitude of MetS was higher. Furthermore, Low physical activity, parity ≥4,
injectable type of contraceptive, and HC use for >48 months were significantly associated with
MetS among the study participants. Therefore, regular check-up for multiparous injectable
contraceptives users for longer duration with a sedentary life style should be done to minimize the
occurrence of MetS.
